133 related articles for article (PubMed ID: 21351581)
1. [Quantitative prediction of in vivo drug-drug interactions based on in vitro inhibition or/and induction data for CYP3A4].
Zhang QH; Li Y
Yao Xue Xue Bao; 2010 Aug; 45(8):952-9. PubMed ID: 21351581
[TBL] [Abstract][Full Text] [Related]
2. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
Mano Y; Sugiyama Y; Ito K
J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
[TBL] [Abstract][Full Text] [Related]
3. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
4. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
5. Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data.
Loue C; Tod M
AAPS J; 2014 Nov; 16(6):1309-20. PubMed ID: 25274605
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
7. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
[TBL] [Abstract][Full Text] [Related]
8. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.
Galetin A; Burt H; Gibbons L; Houston JB
Drug Metab Dispos; 2006 Jan; 34(1):166-75. PubMed ID: 16221752
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of models for predicting drug-drug interactions due to induction.
Fahmi OA; Ripp SL
Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1399-416. PubMed ID: 20955108
[TBL] [Abstract][Full Text] [Related]
10. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
11. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.
Galetin A; Hinton LK; Burt H; Obach RS; Houston JB
Curr Drug Metab; 2007 Oct; 8(7):685-93. PubMed ID: 17979656
[TBL] [Abstract][Full Text] [Related]
12. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro.
Fahmi OA; Maurer TS; Kish M; Cardenas E; Boldt S; Nettleton D
Drug Metab Dispos; 2008 Aug; 36(8):1698-708. PubMed ID: 18490437
[TBL] [Abstract][Full Text] [Related]
13. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
14. Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions.
Bonnabry P; Sievering J; Leemann T; Dayer P
Eur J Clin Pharmacol; 1999 Jul; 55(5):341-7. PubMed ID: 10456482
[TBL] [Abstract][Full Text] [Related]
15. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel substrates for human cytochrome P450 2J2.
Lee CA; Neul D; Clouser-Roche A; Dalvie D; Wester MR; Jiang Y; Jones JP; Freiwald S; Zientek M; Totah RA
Drug Metab Dispos; 2010 Feb; 38(2):347-56. PubMed ID: 19923256
[TBL] [Abstract][Full Text] [Related]
17. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of calibration curve-based approaches to predict clinical inducers and noninducers of CYP3A4 with plated human hepatocytes.
Zhang JG; Ho T; Callendrello AL; Clark RJ; Santone EA; Kinsman S; Xiao D; Fox LG; Einolf HJ; Stresser DM
Drug Metab Dispos; 2014 Sep; 42(9):1379-91. PubMed ID: 24924386
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
[TBL] [Abstract][Full Text] [Related]
20. Intestinal first-pass metabolism of CYP3A4 substrates.
Kato M
Drug Metab Pharmacokinet; 2008; 23(2):87-94. PubMed ID: 18445987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
